SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Camurus Begins Dosing in Phase 2b Obesity Study of CAM2056

Camurus has begun dosing in a Phase 2b study of CAM2056 for obesity and overweight.

Related stories